Overview of the current Japanese biotech industry and investment outlook

Asia s Premier Partnering Event for the Biotechnology Industry. Makoto TANIHARA ICS Convention Design, Inc.

Asia s Premier Partnering Event for the Biotechnology Industry Makoto TANIHARA ICS Convention Design, Inc. February 2013 0 Overview Event Outline BioJapan 2013 -World Business Forum- Date: October 9 (Wed.)-

Regenerative Medicine in Japan

Cell & Gene Therapy World 2017 Regenerative Medicine in Japan January 19, 2017 Table of Contents Section Title Page # Japanese Regenerative Medicine Market Participants 3 Regenerative Medicine R&D in Japan

QIAGEN Sample & Assay Technologies From Discovery to Patient

QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this

Financial Results FY2016

Financial Results FY2016 (January to December 2016) Carna Biosciences, Inc. Stock Code:4572 1 FY2016 Key Highlights Japan Patent Office granted a patent for CDC7/ASK inhibitor in January. Opened a research

Biotechnology - Therapeutics/Diagnostics Private/independent Companies All units in USD M Year

Biotechnology - Therapeutics/Diagnostics Private/ Companies All units in USD M Year 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2013 2014 Grand Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct

Insight to Gene Techno Science Co.,Ltd

Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed

Zephyr Biotech Report

Zephyr Biotech Report May 2015 1: PE, VC and DC The following report details mergers and acquisitions activity in the biotech sector in May 2015 using data from the Zephyr database. It focuses on global

Course Agenda. Day One

Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

AltraGen Senior management leadership offsite Day 1: Introduction

AltraGen Senior management leadership offsite Day 1: Introduction 0 AltraGen outsells its competitors because it offers what no one else can a complete product portfolio in pharmaceuticals Why we have

PMDA s Efforts in Medicinal Area

PMDA s Efforts in Medicinal Area Takao Yamori, Ph.D. Director of Center for Product Evaluation and Deputy Director General of the Office of Review Innovation PMDA, Japan 26th Annual EuroMeeting 25-27 March

Valuing and Licensing Intellectual Property. Richard Williams

c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations

Post-Recession Life Sciences: Achieving Success in the Current Economic Environment

1 2 Post-Recession Life Sciences: Achieving Success in the Current Economic Environment Panelists Moderated by: James C. Chapman, Partner, Foley & Lardner LLP Speakers: Camille D. Samuels, Managing Director,

Biotech in Japan: leveraging unexploited opportunities. Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare

Biotech in Japan: leveraging unexploited opportunities Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare 1 Contents 1. Japan s biotech market 2. Players: emerging biotech start-ups

Centre for NanoHealth

Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,

CDASH Clinical Data Acquisition Standards Harmonization

CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future

QIAGEN - Financials. Roland Sackers Chief Financial Officer. Sample & Assay Technologies -1- QIAGEN Analyst and Investor Day, February 14, 2008

QIAGEN - Financials -1- Roland Sackers Chief Financial Officer Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking

Non-clinical Assessment Requirements

Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance

Woking. q business confidence report

Woking q1 business confidence report Woking q1 report headlines saw a new record in company registrations in Woking when compared to any previous. was a record quarter for company registrations in Woking

Technology funding opportunities at the National Cancer Institute

Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer

University of Michigan Eco-Driving Index (EDI) Latest data: August 2017

University of Michigan Eco-Driving Index () http://www.ecodrivingindex.org Latest data: August 2017 Developed and issued monthly by Michael Sivak and Brandon Schoettle Sustainable Worldwide Transportation

Applying analytics to compliance programs

Applying analytics to compliance programs Get your data to work for you Pharmaceutical Compliance Congress & Best Practices Forum Washington, DC October 21, 2015 Joseph Coniker Principle National Practice

Market Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016

Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial

Gene Techno Science Co., Ltd.

Unlimited drug discovery from the beginning Ticker symbol: 4584 Gene Techno Science Co., Ltd. Financial Results for the Fiscal Year Ended March 2018 May 16, 2018 1 2 Corporate overview Chief Executive

Administration Division Public Works Department Anchorage: Performance. Value. Results.

Administration Division Anchorage: Performance. Value. Results. Mission Provide administrative, budgetary, fiscal, and personnel support to ensure departmental compliance with Municipal policies and procedures,

Realizing the Future that Regenerative Medicine Will Open

470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

Technology Transfer, Academic and Industry Cooperations

Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and

TAIWAN. Who Should Attend? Endless Potential & Opportunities. Where innovations are shaping a new era of intelligent healthcare.

TAIWAN Where innovations are shaping a new era of intelligent healthcare World-class medical centers and hospitals Over 1800 biotech companies Best healthcare system in the world Top-ranked life science

Oryzon Genomics SA ORY.SM MADRID Buy

Jotin Marango, M.D., Ph.D., (646) 616-2780 jmarango@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH November 13, 2018 Healthcare: Biotechnology Oryzon Genomics SA ORY.SM

Zephyr Biotech Report

Zephyr Biotech Report September 2013 1: PE, VC and DC The following report details mergers and acquisitions activity in the biotech sector in September 2013 using data from the Zephyr database. It focuses

World Congress on Industrial Biotechnology May, 2014

World Congress on Industrial Biotechnology May, 2014 1 The Value Proposition Leader in precision gene editing RTDS Non transgenic, non GMO platform RTDS Broadly applicable across many organisms Significant

Stock Price Valuation

-1- Aug25, 2011 Mebiopharm(TOKYO AIM 4580) Devote to develop the anti-cancer drugs with Drug Delivery System (DDS) by using its unique technology of liposome Market Cap:JPY310mil Progress in development

Financial Results FY2018 Q3

Financial Results FY2018 Q3 (January to September 2018) Carna Biosciences, Inc. Stock Code:4572 1 FY2018 Q3 Key Highlights Established the clinical development team to initiate clinical trials of Carnaʼs

Innovative collaboration system on ips cell technologies

Innovative collaboration system on ips cell technologies Kyoto University Founded in 1897 National Innovation System, Competition and Cooperation June 11, 2009 Yutaka Teranishi, Ph.D. Kyoto University

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges

Life Sciences Financing Summary EU August 2017

EU August 2017 In May 2017, we saw a sharp increase in private investments in Biotech (Therapeutic and ) companies at EUR 181m, up over twofold from the previous month, with an average deal size of EUR

European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai

European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai 1 Overview 1. Overview European Biotechs / Clusters 2. Trends in the Biotech & Pharma Venture Valuation: Independent assessment

2017 KEY INSIGHTS ON. Employee Attendance and Tardiness

2017 KEY INSIGHTS ON Employee Attendance and Tardiness THE AVERAGE NUMBER OF MINUTES THAT EMPLOYEES IN THE XIMBLE SYSTEM ARE LATE IS MINUTES. 114.2 MINUTES Statistical sample of 263258 clock-in records,

Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion

News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

Financial Results FY2017

Financial Results FY2017 (January to December 2017) Carna Biosciences, Inc. Stock Code:4572 1 Building a Sustainable Company Continuously Discovering and Delivering Innovative Therapies for Patients by

Electric Forward Market Report

Mar-01 Mar-02 Jun-02 Sep-02 Dec-02 Mar-03 Jun-03 Sep-03 Dec-03 Mar-04 Jun-04 Sep-04 Dec-04 Mar-05 May-05 Aug-05 Nov-05 Feb-06 Jun-06 Sep-06 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Apr-08 Jun-08 Sep-08 Dec-08

Strategic vision of Pharma Market

Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected

5 Star London Hotels - Example Report

5 Star London Hotels - Example Report January 2018 CONTENTS Your Benchmark Report Website Traffic Conversion Rates Ecommerce Performance AdWords Spend Your Traffic Index Your Conversion Rate Index Your

Welcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese

For personal use only

i-bodies a new class of protein therapeutics to treat human disease Biotech meets Broker: September 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment

Axel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK

Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies

Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1

Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted

AnGes MG (TSE Mothers 4563)

Bio-Venture Company Report AnGes MG (TSE Mothers 4563) Bio-venture aiming to be a global innovator in genetic medicine Market cap: 17.17 billion Stock price: 54,900(Dec. 24) Assumed range (2 years): 16.0

Translational Research

Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic

TL 9000 Quality Management System. Measurements Handbook. BRR Examples

Quality Excellence for Suppliers of Telecommunications Forum (QuEST Forum) TL 9000 Quality Management System Measurements Handbook Copyright 2012 QuEST Forum Version 1.0 7.2 7.2.1 Basic Calculation Example

Gene Techno Science Co., Ltd.

Security Code:4584 Gene Techno Science Co., Ltd. Financial Results for 2Q/FY2018 (Fiscal Year Ending March 2019) November 6, 2018 Cautionary Statement This information material is provided for understanding

Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries

Fujifilm Growth Strategy with the Acquisition of Wako Pure Chemical Industries FUJIFILM Holdings Corporation Chairman and Chief Executive Officer Shigetaka Komori December 15, 2016 Key Business Areas Expanding

Konica Minolta to Acquire Ambry Genetics (US)

Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine

2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA)

010/SOM/LSIF/00 Opening Remarks Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA) Life Sciences Innovation Forum Sendai, Japan 18-19 September 010 Message From JPMA President APEC Life

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016 Cellular Tumor

REIMAGINING DRUG DEVELOPMENT:

Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

Experiences of a Bioinformatics Company in. Dr Othmar Pfannes 4 November 2016 Basel

Experiences of a Bioinformatics Company in Dr Othmar Pfannes 4 November 2016 Basel Agenda About Genedata Genedata in Japan Q&A 2 Genedata Snapshot Roots Established in 1997 Privately owned Headquartered

BIOPHARMACEUTICALS Availability, Diffusion, Sustainability. Massimo Riccaboni University of Florence & CERM, Rome

BIOPHARMACEUTICALS Availability, Diffusion, Sustainability Massimo Riccaboni University of Florence & CERM, Rome The need for a precise definition of biopharmaceutical products Since the 1980s, the general

2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth

2009 INVESTOR DAY BioPharmaceuticals Ken Frank President BioPharmaceuticals December 17, 2009 Sustainable, Profitable Growth Life Sciences FY 2009 Total Sales $2,329.2 (amounts shown in millions) BioPharmaceuticals

Fine Chemicals Japan 2017

Fine Chemicals Japan 2017 Exhibition of Advanced Chemical Products for the Manufacturing Industries - Fine Chemicals for A Better Life - Date: 19 th (Wed.) April 21 st (Thur.) April 2017 Venue: Tokyo Big

Traffic Department Anchorage: Performance. Value. Results.

Traffic Department Anchorage: Performance. Value. Results. Mission Promote safe and efficient area-wide transportation that meets the needs of the community and the Anchorage Municipal Traffic Code requirements.

Leading The Way in Life Science Technologies. Planning Calendar

Leading The Way in Life Science Technologies 2018 Planning Calendar January 1 Reservation: 11/30/17 Material: 12/7/17 l Kinase Assays l Immunotherapy l Stem-Cell Manufacturing Peptalk, January 8 12, San

N4 Pharma Investor Presentation

N4 Pharma Investor Presentation November 2017 Introduction o Established in 2014 o Specialist pharmaceutical company with two divisions: o Reformulation of existing generic drugs and o Silica nanoparticle

World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for

Table of Contents SCOPE AND METHODOLOGY... 8 Market Definition... 8 Market Scope... 8 Market Stakeholders... 9 Research Methodology... 10 Secondary and Primary Research Methodology... 10 Market Size Estimation

Looking beyond ICH-E9 in the Era of Global Drug Development

Biostatistics Summer Workshop 2012 Looking beyond ICH-E9 in the Era of Global Drug Development Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency This is not an official

Chapter 6 Planning and Controlling Production: Work-in-Process and Finished-Good Inventories. Omar Maguiña Rivero

Chapter 6 Planning and Controlling Production: Work-in-Process and Finished-Good Inventories Learning Objectives At the end of the class the student will be able to: 1. Describe the production budget process

MARINE BIOINFORMATICS & NANOBIOTECHNOLOGY - PBBT305

MARINE BIOINFORMATICS & NANOBIOTECHNOLOGY - PBBT305 UNIT-1 MARINE GENOMICS AND PROTEOMICS 1. Define genomics? 2. Scope and functional genomics? 3. What is Genetics? 4. Define functional genomics? 5. What

Financial results for the fiscal year ending March 2016

Unlimited Drug Discovery from the Beginning Financial results for the fiscal year ending March 2016 20 th May, 2016 Stock Code: 4584 0 1 Representative Establishment March 2001 Masanari Kawaminami, President

Execution of Share Exchange Agreement and Conversion of Advanced Cell Technology and Engineering into Wholly-Owned Subsidiary of Gene Techno Science

January 17, 2019 Gene Techno Science Co., Ltd. Code: 4584 (TSE Mothers) Masaharu Tani, President & CEO Execution of Share Exchange Agreement and Conversion of Advanced Cell Technology and Engineering into

BY PEOPLE. WITH PEOPLE. FOR PEOPLE.

BY PEOPLE. WITH PEOPLE. FOR PEOPLE. :: 4SC AG, ENNO SPILLNER KORRELATION UNTERNEHMENSNACHRICHTEN & UNTERNEHMENSBEWERTUNG BERLIN, 19. MÄRZ 2013 FORWARD LOOKING STATEMENTS This presentation may contain projections

Lehman Brothers Global Healthcare Conference

Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007 Safe Harbor Except for the historical information contained herein, this

How Targets Are Chosen. Chris Wayman 12 th April 2012

How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench

Introducing Immunomic Therapeutics Expanded Technology Platform: UNITETM

Introducing Immunomic Therapeutics Expanded Technology Platform: UNITETM Immunomic Therapeutics is a privately-held, clinical stage biotech company developing modern DNA and RNA vaccines for allergic diseases

QUARTERLY FORECAST REPORT 2ND QUARTER

QUARTERLY FORECAST REPORT 2ND QUARTER 216 77 Sundial Ave. Suite 51 W. Manchester, NH 313 E-mail: itr@itreconomics.com Quarterly Forecast Report Table of Contents Definitions & Methodology... 3 MTI Average

The University of Toledo Audit Committee Meeting. April 19, 2010

The University of Toledo Audit Committee Meeting April 19, 2010 FY2010 Internal Audit Schedule Internal Audit Activity KEY RISK AREAS 2009 2010 JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN ACADEMIC

Overview of Pharmaceutical Business at JT

Overview of Pharmaceutical Business at JT July 4, 2017 Muneaki Fujimoto President, Pharmaceutical Business 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. These statements

assessment regarding the effects of accuracy checks for infusion and syringe pumps on other clinical operations.

Introduction Materials As per the revised Pharmaceutical Affairs Law announced in July 2004, infusion and syringe pumps are classified as specially controlled medical devices. In our hospital, all infusion

i-bodies a new class of protein therapeutics to treat human disease

i-bodies a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is

Accelerating Takeda s R&D Success

Accelerating Takeda s R&D Success Our Mission is to Serve Patients We do more than develop medicines We innovate to improve patients lives Takeda R&D places the patient at the center of everything we do

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease

Zephyr Biotech Report

Zephyr Biotech Report March 2014 1: PE, VC and DC The following report details mergers and acquisitions activity in the biotech sector in March 2014 using data from the Zephyr database. It focuses on global

California Independent System Operator Corporation. California ISO. Import resource adequacy. Department of Market Monitoring

k California Independent System Operator Corporation California ISO Import resource adequacy September 10, 2018 Department of Market Monitoring Summary This report provides an update of analysis and trends

Zephyr Biotech Report

Zephyr Biotech Report July 2014 1: PE, VC and DC The following report details mergers and acquisitions activity in the biotech sector in July 2014 using data from the Zephyr database. It focuses on global

Personalized CAR-T Immunotherapy Platform

GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd.

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. December 2, 2013 Background March 28, 2013 Capital alliance: DSP took a 1.5billion

List of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.

Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal

Development Stage of Therapeutic Vaccines: The Regulator s View

Development Stage of Therapeutic Vaccines: The Regulator s View Thomas Hinz Head, Section Therapeutic Vaccines Paul Ehrlich Institute, Germany thomas.hinz@pei.de 1 DISCLAIMER This is the personal views

A new stage of China s Copper Consumption

A new stage of China s Copper Consumption Zhong Min Vice General Manager Jinrui Futures Co.,Ltd, Jiangxi Copper Corporation 22/02/2013 1 A new stage of China s Copper Consumption Will the slow-up in China

Career Growth Areas in Physiology / Pharmacology

Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical

Physiomics Plc. ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2015

The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six month period

Project Risk Management Bootcamp. Contents are subject to change. For the latest updates visit

Bootcamp Page 1 of 7 Why Attend The overall aim of this program is to enable participants to plan, manage and control project risks. Moreover, participants will be able to develop project risk management

Korean Perspective : Recent Trends in the Regulation of Biopharmaceuticals

Korean Perspective : Recent Trends in the Regulation of Biopharmaceuticals Dec. 4, 2017 Heajeong Doh Ministry of Food and Drug Safety, Korea [ Table of Contents] Introduction of MFDS Biopharmaceuticals

Formalize Corporate Social Responsibility Information Disclosure System and Improve Transparency (also through the supply chain reporting practices)

Formalize Corporate Social Responsibility Information Disclosure System and Improve Transparency (also through the supply chain reporting practices) Dr. Nelmara Arbex, Deputy Chief Executive, Guidance,

Strategic Overview of the Biotechnology Industry

Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech

UBT Performance Tracking Tool

SECTION 4 COMPETENCY: Improving Performance UBT Performance Tracking Tool Purpose The Unit-Based Team Performance Tracking Tool provides a picture of how the UBT s actions impact overall performance. Experience

Dealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.

Dealdoc Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon Oct 18 2010 Marketing agreement for Recombinant Human Insulin, Glargine, Aspart

Traffic Division Public Works Department Anchorage: Performance. Value. Results.

Mission Promote safe and efficient area-wide transportation that meets the needs of the community and the Anchorage Municipal Traffic Code requirements. Direct Services Design, operate and maintain the